Abstract:INTRODUCTION. Sepsis is characterized by the development of adaptive immune cell alterations under hypoxia or toxin condition induced by pathogens. Mesenchymal stem cell (MSC) s ́ beneficial effects with immunosuppressive capacity in preclinical models of acute sepsis have been witnessed but meet difficulties to bedside treatments. MSCs could induce various effects on lymphocytes depending on environmental sensitivity. T helper 17(Th17) and regulatory T (Treg) cells in T cells differentiating play a vital role during inflammation process. However, T lymphocyte differentiation towards Th17 and Treg cells are not completely understood under different septic conditions. OBJECTIVES. The aim of the current study was to evaluate whether lipopolysaccharide (LPS) or hypoxia could directly impact Treg and Th17 cells differentiation in vitro and the effects of MSCs. METHODS. Purified CD4+ T cells isolated by positive CD4 selection from mice spleen were treated with LPS or at hypoxia condition. We investigated T cells differentiation towards Treg and Th17 with direct or indirect MSCs treatment respectively by adding MSCs into cell-culture inserts directly or into upper champers, followed by neutralization of TGF-β1 with anti-TGF-β1 antibody in the co-culture medium. Phenotypes of Treg and Th17 cells were identified by flowcytometry. T-cell proliferation was tested by cell-counting kit-8 assay. Supernatant was harvested from cell culture frozen at -80 C for cytokine analysis by enzyme-linked immunosorbent assay kits. RESULTS. Treg/Th17 ratio significantly decreased after 48h LPS stimulation with dose above 100ng/ml or hypoxia. MSCs could significantly reversed reduced Treg/Th17 induced by LPS or hypoxia with no difference between direct and indirect co-culture groups. Moreover, TGF-β1 levels in MSCs treatment whether upon LPS or hypoxia were much higher than LPS or hypoxia group. Meanwhile, neutralizing TGF-β1 with anti-TGF-β1 antibody inhibited the role of MSCs improving reduced Treg/Th17 upon LPS stimulation. T cell proliferative capacity in MSCs treatment group upon LPS was higher than that in LPS group. The effects of MSCs were significantly blocked by anti-TGFβ1 antibody. CONCLUSIONS. The data suggested that LPS priming and hypoxia directly impact T lymphocyte differentiation favoring Th17 rather than Treg phenotype resulting to reduced Treg/Th17 in vitro. MSCs treatment could reverse the reduced Treg/Th17. The main mechanisms was attributed mainly to TGFβ1 secreted by MSCs rather than cell-to-cell contact. GRANT ACKNOWLEDGMENT. This work was supported by the National Natural Science Foundations of China (grants 81571874 and 81501705), the Natural Science Foundation of Jiangsu Province of China (grants BK2014134).

Improved therapeutic consistency and efficacy of CD317+ MSCs through stabilizing TSG6 by PTX3

CD317+ MSCs expanded with chemically defined media have enhanced immunological anti-inflammatory activities

Marrow Mesenchymal Stem Cells Transduced with Tpo/Fl Genes As Support for Ex Vivo Expansion of Hematopoietic Stem/Progenitor Cells

An Improved Protocol for Isolating and increasing the Multiple Differentiation Potentials of Mesenchymal Stem Cells from Human Bone Marrow

Dissecting Heterogeneity Reveals a Unique BAMBIhighMFGE8high Subpopulation of Human UC-MSCs

Ex Vivo Expansion and Transplantation of Hematopoietic Stem/progenitor Cells Supported by Mesenchymal Stem Cells from Human Umbilical Cord Blood.

Expansion of human bone marrow-derived mesenchymal stromal cells with enhanced immunomodulatory properties

3D spheroid culture synchronizes heterogeneous MSCs into an immunomodulatory phenotype with enhanced anti-inflammatory effects

Improved therapeutic consistency and efficacy of mesenchymal stem cells expanded with chemically defined medium for systemic lupus erythematosus

IDDF2018-ABS-0243 TSG-6 released by mesenchymal stem cells derived from human induced pluripotent stem cells alleviate colitis through the regulation of CD44

Exosomes Originating from MSCs Stimulated with TGF‐β and IFN‐γ Promote Treg Differentiation

Serum-Free Medium Enhances the Therapeutic Effects of Umbilical Cord Mesenchymal Stromal Cells on a Murine Model for Acute Colitis

Improved osteogenesis and upregulated immunogenicity in human placenta-derived mesenchymal stem cells primed with osteogenic induction medium

Mesenchymal Stem/stromal Cells Primed by Inflammatory Cytokines Alleviate Psoriasis-Like Inflammation Via the TSG-6-neutrophil Axis

Poster Corner 6: Sepsis and Cardiovascular Dynamics 075-MESENCHYMAL STEM CELLS ALTERED T LYMPHOCYTE DIFFERENTIATION UPON LPS OR HYPOXIA CHALLENGE VIA PARACRINE TRANSFORMING GROWTH FACTOR BETA-1 IN VITRO

TWIST1 and TSG6 are coordinately regulated and function as potency biomarkers in human MSCs

Improved efficacy of mesenchymal stromal cells stably expressing CXCR4 and IL-10 in a xenogeneic graft versus host disease mouse model

Improving the immunomodulatory function of mesenchymal stem cells by defined chemical approach

Strategies to enhance immunomodulatory properties and reduce heterogeneity in mesenchymal stromal cells during ex vivo expansion

Improved Therapeutics of Modified Mesenchymal Stem Cells: an Update

Liver-targeted Delivery of TSG-6 by Calcium Phosphate Nanoparticles for the Management of Liver Fibrosis